Rep. John E. Bradley

Filed: 5/2/2014

 

 


 

 


 
09800SB2187ham002LRB098 10555 ZMM 58174 a

1
AMENDMENT TO SENATE BILL 2187

2    AMENDMENT NO. ______. Amend Senate Bill 2187, AS AMENDED,
3by replacing everything after the enacting clause with the
4following:
 
5    "Section 5. The Clinical Psychologist Licensing Act is
6amended by changing Sections 2 and 7 and by adding Sections
74.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, and 4.8 as follows:
 
8    (225 ILCS 15/2)  (from Ch. 111, par. 5352)
9    (Section scheduled to be repealed on January 1, 2017)
10    Sec. 2. Definitions. As used in this Act:
11        (1) "Department" means the Department of Financial and
12    Professional Regulation.
13        (2) "Secretary" means the Secretary of Financial and
14    Professional Regulation.
15        (3) "Board" means the Clinical Psychologists Licensing
16    and Disciplinary Board appointed by the Secretary.

 

 

09800SB2187ham002- 2 -LRB098 10555 ZMM 58174 a

1        (4) "Person" means an individual, association,
2    partnership or corporation.
3        (5) "Clinical psychology" means the independent
4    evaluation, classification and treatment of mental,
5    emotional, behavioral or nervous disorders or conditions,
6    developmental disabilities, alcoholism and substance
7    abuse, disorders of habit or conduct, the psychological
8    aspects of physical illness. The practice of clinical
9    psychology includes psychoeducational evaluation, therapy,
10    remediation and consultation, the use of psychological and
11    neuropsychological testing, assessment, psychotherapy,
12    psychoanalysis, hypnosis, biofeedback, and behavioral
13    modification when any of these are used for the purpose of
14    preventing or eliminating psychopathology, or for the
15    amelioration of psychological disorders of individuals or
16    groups. "Clinical psychology" does not include the use of
17    hypnosis by unlicensed persons pursuant to Section 3.
18        (6) A person represents himself to be a "clinical
19    psychologist" or "psychologist" within the meaning of this
20    Act when he or she holds himself out to the public by any
21    title or description of services incorporating the words
22    "psychological", "psychologic", "psychologist",
23    "psychology", or "clinical psychologist" or under such
24    title or description offers to render or renders clinical
25    psychological services as defined in paragraph (7) of this
26    Section to individuals, corporations, or the public for

 

 

09800SB2187ham002- 3 -LRB098 10555 ZMM 58174 a

1    remuneration.
2        (7) "Clinical psychological services" refers to any
3    services under paragraph (5) of this Section if the words
4    "psychological", "psychologic", "psychologist",
5    "psychology" or "clinical psychologist" are used to
6    describe such services by the person or organization
7    offering to render or rendering them.
8        (8) "Prescribing psychologist" means a licensed,
9    doctoral level psychologist who has undergone specialized
10    training, has passed an examination accepted by the Board,
11    and has received a current license granting prescriptive
12    authority that has not been revoked or suspended from the
13    Board.
14        (9) "Prescriptive authority" means the authority to
15    prescribe, administer, discontinue, or distribute, without
16    charge, drugs, medicines, or other treatment procedures.
17        (10) "Prescription" means an order for a drug,
18    laboratory test, or any medicines, including controlled
19    substances as defined in the Illinois Controlled
20    Substances Act, devices, or treatments.
21        (11) "Drugs" has the meaning given to that term in the
22    Pharmacy Practice Act.
23        (12) "Medicines" has the meaning given to that term in
24    the Pharmacy Practice Act.
25        (13) "Cross-indicated drug" means a drug that is used
26    for a purpose generally held to be reasonable, appropriate,

 

 

09800SB2187ham002- 4 -LRB098 10555 ZMM 58174 a

1    and within the community standards of practice even though
2    the use is not included in the federal Food and Drug
3    Administration's approved labeled indications for the
4    drug.
5    This Act shall not apply to persons lawfully carrying on
6their particular profession or business under any valid
7existing regulatory Act of the State.
8(Source: P.A. 94-870, eff. 6-16-06.)
 
9    (225 ILCS 15/4.1 new)
10    Sec. 4.1. Prescribing psychologist licensure; prescriptive
11authority. The Board shall grant licensure as prescribing
12psychologists to doctoral level psychologists licensed under
13this Act, including prescriptive authority to prescribe and
14dispense drugs in accordance with Sections 4.2 and 4.3 of this
15Act. The Board shall develop and implement procedures and
16criteria for reviewing educational and training credentials
17for the licensure process in accordance with current standards
18of professional practice.
 
19    (225 ILCS 15/4.2 new)
20    Sec. 4.2. Conditional prescription license.
21    (a) A psychologist may apply to the Board for a conditional
22prescription license, which shall be valid for a period of 2
23years. The Board may extend the duration of a conditional
24prescription license pending the issuance of a prescription

 

 

09800SB2187ham002- 5 -LRB098 10555 ZMM 58174 a

1license issued under Section 4.3 of this Act. The application
2for a conditional prescription license shall be made on a form
3approved by the Board and be accompanied by evidence
4satisfactory to the Board that the applicant:
5        (1) has completed a doctoral program in psychology from
6    a regionally accredited university or professional school
7    or, if the program is not accredited at the time of
8    graduation, completion of a doctoral program in psychology
9    that meets recognized acceptable professional standards as
10    determined by the Board;
11        (2) holds a current and valid license to practice
12    clinical psychology in the State;
13        (3) has graduated with a master's degree in clinical
14    psychopharmacology from a regionally accredited
15    institution that requires students to possess sufficient
16    knowledge of human biology, anatomy, physiology,
17    biochemistry, neuroanatomy, and psychopharmacology to
18    ensure an adequate foundation for the completion of the
19    master's degree; the curriculum shall meet the standards
20    established by the National Register and the Association of
21    State and Provincial Psychology Boards, including:
22            (A) a range of training experiences at different
23        health care facility sites; and
24            (B) instruction in:
25                (i) neurosciences, including neuroanatomy,
26            neurophysiology, and neurochemistry;

 

 

09800SB2187ham002- 6 -LRB098 10555 ZMM 58174 a

1                (ii) pharmacology and psychopharmacology,
2            including pharmacology, clinical pharmacology,
3            psychopharmacology, developmental
4            psychopharmacology, and chemical dependence;
5                (iii) pathophysiology, including normal
6            anatomy and physiological processes, common
7            pathological states, cardiovascular, renal,
8            hepatic, gastrointestinal, neural, and endocrine
9            functions, bioavailability and biodisposition of
10            drugs, variability in drug bioavailability and
11            disposition based upon ethnic and cultural
12            differences, variability in response due to age,
13            gender, disability, and ethnic differences,
14            medical conditions affecting biodisposition, and
15            side effects, including contraindications;
16                (iv) physical and laboratory assessment,
17            including familiarity with medical charts,
18            physical exams, and laboratory and radiological
19            examinations;
20                (v) pharmacotherapeutics, including
21            pharmacotherapeutic interactions, psychotherapy
22            and pharmacotherapy interactions, drug
23            interactions, compliance maintenance programs,
24            computer-based aids to practice, and
25            pharmacoepidemiology;
26                (vi) professional, legal, ethical, and

 

 

09800SB2187ham002- 7 -LRB098 10555 ZMM 58174 a

1            interprofessional issues relevant to the practice
2            of psychology involving psychopharmacology;
3                (vii) continuous quality improvement processes
4            and measures; and
5                (viii) clinical outcomes research.
6        (4) within the 5 years immediately preceding the date
7    of application, has been certified by the applicant's
8    supervising physician, who is authorized to prescribe
9    psychotropic medication, has experience with a full range
10    of complex mental disorders and a mix of diagnoses, and
11    generally prescribes psychotropic medication to his or her
12    patients in the normal course of his or her clinical
13    medical practice, and one other expert in clinical
14    psychopharmacology, which may be the Director of Training
15    of a clinical psychopharmacology training program, as
16    having successfully completed a supervised and relevant
17    clinical experience approved by the Board of no less than
18    an 80-hour practicum in clinical assessment and
19    pathophysiology and an additional supervised practicum of
20    at least 400 hours treating no fewer than 100 patients with
21    a full range of complex mental disorders and a mix of
22    diagnoses; both practica shall be supervised by an
23    appropriately trained physician who is authorized to
24    prescribe psychotropic medication, has experience with a
25    full range of complex mental disorders and a mix of
26    diagnoses, and generally prescribes psychotropic

 

 

09800SB2187ham002- 8 -LRB098 10555 ZMM 58174 a

1    medication to his or her patients in the normal course of
2    his or her clinical medical practice and determined by the
3    Board as competent to train the applicant in the treatment
4    of a diverse patient population; both practica shall take
5    place in a health care setting, with a portion of the
6    clinical experience occurring in one or more of the
7    following settings:
8            (A) correctional facilities;
9            (B) federally qualified health centers, as defined
10        in the federal Social Security Act (42 U.S.C. 1396d);
11            (C) community service agencies serving the
12        seriously mentally ill;
13            (D) local, State, or federal facilities; or
14            (E) shelters or any other facilities serving the
15        needs of survivors of domestic violence.
16        (5) has passed an examination authorized by the Board
17    to determine his or her fitness to receive a license;
18        (6) has sufficient malpractice insurance to satisfy
19    the rules adopted by the Board that will cover the
20    applicant during the period the conditional prescription
21    license is in effect;
22        (7) has an agreement with one or more of the health
23    care settings described in paragraph (4) of subsection (a)
24    of this Section with regard to services; and
25        (8) meets all other requirements, as determined by rule
26    of the Board, for obtaining a conditional prescription

 

 

09800SB2187ham002- 9 -LRB098 10555 ZMM 58174 a

1    license.
2    (b) The Board shall issue a conditional prescription
3license if it finds that the applicant has met the requirements
4of subsection (a) of this Section.
5    (c) A psychologist with a conditional prescription license
6may only prescribe psychotropic medication pursuant to Section
74.5 of this Act under the supervision of a licensed physician
8who is authorized to prescribe psychotropic medication, has
9experience with a full range of complex mental disorders and a
10mix of diagnoses, and generally prescribes psychotropic
11medication to his or her patients in the normal course of his
12or her clinical medical practice in such a manner that reflects
13the clinical focus of the conditional prescribing psychologist
14subject to the following conditions:
15        (1) the psychologist shall continue to hold a current
16    license to practice psychology in Illinois and continue to
17    maintain malpractice insurance;
18        (2) the psychologist shall inform the Board of the name
19    of the physician under whose supervision the psychologist
20    will prescribe psychotropic medication and promptly inform
21    the Board of any change of the supervising physician; and
22        (3) a physician supervising a psychologist prescribing
23    psychotropic medication under a conditional prescription
24    license shall inform the Board that he or she is
25    supervising the psychologist.
26    (d) A written supervision agreement between a psychologist

 

 

09800SB2187ham002- 10 -LRB098 10555 ZMM 58174 a

1and his or her supervising physician is required for all
2psychologists practicing under a conditional prescription
3license issued pursuant to this Section. A supervising
4physician shall delegate prescriptive authority to a
5conditionally licensed prescribing psychologist as part of a
6written supervision agreement.
7    (e) The written supervision agreement shall govern the
8working relationship between the psychologist and his or her
9supervising physician during the supervision period.
10Supervision does not require an employment relationship
11between the supervising physician and psychologist.
12    (f) Methods of communication shall be available for
13consultation with the supervising physician in person or by
14telecommunications in accordance with established written
15guidelines as set forth in the supervision agreement.
16    (g) The psychologist shall provide his or her supervising
17physician with all relevant information that is necessary for
18the supervising physician to adequately supervise the
19psychologist's training under this Section.
20    (h) Supervision under all supervision agreements shall be
21adequate if the supervising physician does each of the
22following:
23        (1) consults with the psychologist in order to discuss
24    a patient's history, diagnoses, medication choices, dosage
25    levels and all other relevant information;
26        (2) maintains the ability to alter a patient's

 

 

09800SB2187ham002- 11 -LRB098 10555 ZMM 58174 a

1    treatment plan if necessary;
2        (3) reviews all of the psychologist's cases involving
3    the use of prescriptive authority at weekly consultation
4    meetings; and
5        (4) provides his or her assessment of the
6    psychologist's suitability to prescribe psychotropic
7    medication independently at the time the psychologist is
8    prepared to apply for a prescription license.
9    (i) A supervising physician shall be individually
10responsible for the acts and omissions of the psychologist
11involving the use of prescriptive authority that occur while
12the psychologist is under the supervising physician's
13supervision. This provision does not relieve the psychologist
14from liability for his or her acts and omissions.
 
15    (225 ILCS 15/4.3 new)
16    Sec. 4.3. Prescription license.
17    (a) A psychologist may apply to the Board for a
18prescription license. The application shall be made on a form
19approved by the Board and be accompanied by evidence
20satisfactory to the Board that the applicant:
21        (1) has been issued a conditional prescription license
22    pursuant to Section 4.2 of this Act and has successfully
23    completed 2 years of prescribing psychotropic medication
24    under a conditional prescription license as attested to by
25    the supervising licensed physician and one other expert in

 

 

09800SB2187ham002- 12 -LRB098 10555 ZMM 58174 a

1    clinical psychopharmacology, which may be the Director of
2    Training of a clinical psychopharmacology training
3    program;
4        (2) has successfully undergone a process of
5    independent peer review approved by the Board;
6        (3) holds a current license to practice clinical
7    psychology in Illinois;
8        (4) has malpractice insurance in place, sufficient to
9    satisfy the rules adopted by the Board, that will cover the
10    applicant as a prescribing psychologist;
11        (5) has an agreement with one or more of the health
12    care settings described in paragraph (4) of subsection (a)
13    of Section 4.2 with regard to services; and
14        (6) meets all other requirements for obtaining a
15    prescription license, as determined by rule of the Board.
16    (b) The Board shall issue a prescription license if it
17finds that the applicant has met the requirements of subsection
18(a) of this Section.
19    (c) A psychologist with a prescription license may only
20prescribe psychotropic medication pursuant to the provisions
21of this Act if the psychologist:
22        (1) continues to hold a current license to practice
23    psychology in Illinois and continues to maintain
24    malpractice insurance;
25        (2) annually satisfies the continuing education
26    requirements for prescribing psychologists set by the

 

 

09800SB2187ham002- 13 -LRB098 10555 ZMM 58174 a

1    Board, which shall be no fewer than 20 hours each year and
2    a portion of which shall address continuous quality
3    improvement processes and measures and clinical outcomes
4    research; and
5        (3) maintains a written collaborative agreement with a
6    collaborating physician pursuant to Section 4.4 of this
7    Act.
 
8    (225 ILCS 15/4.4 new)
9    Sec. 4.4. Written collaborative agreements.
10    (a) A written collaborative agreement is required for all
11prescribing psychologists practicing under a prescription
12license issued pursuant to Section 4.3 of this Act. A
13collaborating physician shall be a licensed physician who is
14authorized to prescribe psychotropic medications and generally
15prescribes medications to his or her patients in the normal
16course of his or her clinical medical practice. The
17collaborating physician shall delegate prescriptive authority
18to a prescribing psychologist as part of a written
19collaborative agreement.
20    (b) The written collaborative agreement shall describe the
21working relationship of the prescribing psychologist with the
22collaborating physician and shall delegate prescriptive
23authority as provided in this Act. Collaboration does not
24require an employment relationship between the collaborating
25physician and prescribing psychologist. Absent an employment

 

 

09800SB2187ham002- 14 -LRB098 10555 ZMM 58174 a

1relationship, an agreement may not restrict third-party
2payment sources accepted by the prescribing psychologist. For
3the purposes of this Section, "collaboration" means the
4relationship between a prescribing psychologist and a
5collaborating physician with respect to the delivery of
6prescribing services in accordance with (1) the prescribing
7psychologist's training, education, and experience and (2)
8collaboration and consultation as documented in a jointly
9developed written collaborative agreement.
10    (c) The agreement shall promote the exercise of
11professional judgment by the prescribing psychologist
12corresponding to his or her education and experience.
13    (d) The collaborative agreement shall not be construed to
14require the personal presence of a physician at the place where
15services are rendered. Methods of communication shall be
16available for consultation with the collaborating physician in
17person or by telecommunications in accordance with established
18written guidelines as set forth in the written agreement.
19    (e) Collaboration and consultation pursuant to all
20collaboration agreements shall be adequate if a collaborating
21physician does each of the following:
22        (1) participates in the joint formulation and joint
23    approval of orders or guidelines with the prescribing
24    psychologist and he or she periodically reviews the
25    prescribing phychologist's orders and the services
26    provided patients under the orders in accordance with

 

 

09800SB2187ham002- 15 -LRB098 10555 ZMM 58174 a

1    accepted standards of medical practice and prescribing
2    psychologist practice;
3        (2) provides collaboration and consultation with the
4    prescribing psychologist at least once a month; and
5        (3) is available through telecommunications for
6    consultation on medical problems, complications,
7    emergencies, or patient referral.
8    (f) The written collaborative agreement shall contain
9provisions detailing notice for termination or change of status
10involving a written collaborative agreement, except when the
11notice is given for just cause.
12    (g) A copy of the signed written collaborative agreement
13shall be available to the Department upon request to either the
14prescribing psychologist or the collaborating physician.
15    (h) Nothing in this Section shall be construed to limit the
16authority of a prescribing psychologist to perform all duties
17authorized under this Act.
18    (i) A prescribing psychologist shall inform each
19collaborating physician of all collaborative agreements he or
20she has signed and provide a copy of these to any collaborating
21physician.
 
22    (225 ILCS 15/4.5 new)
23    Sec. 4.5. Controlled substance prescriptive authority.
24    (a) When authorized to prescribe controlled substances, a
25prescribing psychologist shall file, in a timely manner, any

 

 

09800SB2187ham002- 16 -LRB098 10555 ZMM 58174 a

1individual Drug Enforcement Agency registrations and
2identification numbers with the Board.
3    (b) The Board shall maintain current records of every
4prescribing psychologist, including Drug Enforcement Agency
5registration and identification numbers.
6    (c) The delegated prescriptive authority under this Act is
7limited to:
8        (1) a drug that is classified as an antianxiety,
9    antidepressant, or antipsychotic central nervous system
10    drug in the most recent publication of Drug Facts and
11    Comparisons (published by the Facts and Comparisons
12    Division of J.B. Lippincott Company);
13        (2) a drug that is a cross-indicated drug for the
14    central nervous system drug classification, described in
15    paragraph (1) of this subsection (c), according to any of
16    the following:
17            (A) the American Psychiatric Press Textbook of
18        Psychopharmacy;
19            (B) Current Clinical Strategies for Psychiatry;
20            (C) Drug Facts and Comparisons; or
21            (D) a publication with a focus and content similar
22        to publications described in items (A), (B), and (C);
23        or
24        (3) a drug that is:
25            (A) classified in a central nervous system drug
26        category or classification (according to Drug Facts

 

 

09800SB2187ham002- 17 -LRB098 10555 ZMM 58174 a

1        and Comparisons) that is created after March 12, 2002;
2        and
3            (B) prescribed for the treatment of a mental
4        illness (as defined in the most recent publication of
5        the American Psychiatric Association's Diagnostic and
6        Statistical Manual of Mental Disorders or the World
7        Health Organization's International Statistical
8        Classification of Diseases and Related Health Problems
9        Chapter titled Mental and Behavioural Disorders).
10    (d) To prescribe controlled substances under this Section,
11a prescribing psychologist shall obtain a mid-level
12practitioner controlled substance license.
13    (e) The collaborating physician shall file with the
14Department notice of delegation of prescriptive authority and
15termination of such delegation in accordance with rules of the
16Department. Upon receipt of this notice of delegating authority
17to prescribe any Schedule II through V controlled substances,
18the prescribing psychologist shall be eligible to register for
19a mid-level practitioner controlled substance license under
20Section 303.05 of the Illinois Controlled Substances Act.
21    (f) Nothing in this Act shall be construed to limit the
22method of delegation that may be authorized by any means,
23including, but not limited to, oral, written, electronic,
24standing orders, protocols, guidelines, or verbal orders.
25    (g) Nothing in this Section shall be construed to prohibit
26generic substitution.

 

 

09800SB2187ham002- 18 -LRB098 10555 ZMM 58174 a

1    (h) Any prescribing psychologist who writes a prescription
2for a controlled substance without having a valid appropriate
3authority may be fined by the Department not more than $50 per
4prescription and the Department may take any other disciplinary
5action provided for in this Act.
 
6    (225 ILCS 15/4.6 new)
7    Sec. 4.6. Endorsement.
8    (a) Individuals who are already licensed as medical or
9prescribing psychologists in another state may apply for an
10Illinois prescription license by endorsement from that state,
11or acceptance of that state's examination. Applicants from
12other states may not be required to pass an examination in
13Illinois if they meet requirements set forth in this Act and
14its rules, such as proof of education, testing, and experience.
15The Board shall not issue a license until it has received and
16approved all documentation.
17    (b) Individuals who have fulfilled some, but not all, of
18another state's requirements for a conditional prescription
19license shall be given credit for his or her completion of the
20other state's requirements to the extent that such requirements
21are deemed by the Board to be substantially equivalent to the
22requirements of Section 4.2 of this Act. Fulfillment of another
23state's requirements shall count towards the completion of the
24requirements for a conditional prescription license under this
25Act. The Board shall not grant credit for the fulfillment of

 

 

09800SB2187ham002- 19 -LRB098 10555 ZMM 58174 a

1such requirements under Section 4.2 of this Act until it has
2received and approved all documentation.
3    (c) Individuals who graduated from the Department of
4Defense Psychopharmacology Demonstration Project may apply for
5an Illinois prescription license by endorsement. Applicants
6from the Department of Defense Psychopharmacology
7Demonstration Project may not be required to pass an
8examination in Illinois if they meet requirements set forth in
9this Act and its rules, such as proof of education, testing,
10and experience. The Board shall not issue a license until it
11has received and approved all documentation.
 
12    (225 ILCS 15/4.7 new)
13    Sec. 4.7. State Board of Pharmacy interaction.
14    (a) The Board shall transmit to the State Board of Pharmacy
15an annual list of prescribing psychologists containing the
16following information:
17        (1) the name of the prescribing psychologist;
18        (2) the prescribing psychologist's identification
19    number assigned by the Board; and
20        (3) the effective dates of the prescribing
21    psychologist's licensure.
22    (b) The Board shall promptly forward to the Board of
23Pharmacy the names and titles of psychologists added to or
24deleted from the annual list of prescribing psychologists.
25    (c) The Board shall notify the State Board of Pharmacy, in

 

 

09800SB2187ham002- 20 -LRB098 10555 ZMM 58174 a

1a timely manner, upon termination, suspension, or
2reinstatement of a psychologist's licensure as a prescribing
3psychologist.
 
4    (225 ILCS 15/4.8 new)
5    Sec. 4.8. Rulemaking authority of the Board; prescription
6licenses.
7    (a) The Board shall adopt rules providing for the
8procedures to be followed in obtaining conditional
9prescription licenses and prescription licenses authorized to
10be issued under Sections 4.2 and 4.3 and rules providing for
11the procedures to be followed for their renewal. The Board may
12set reasonable application and renewal fees.
13    (b) The Board shall adopt rules establishing the grounds
14for denial, suspension, or revocation of a conditional
15prescription license and a prescription license, including a
16provision for suspension or revocation of a license to practice
17psychology upon the suspension or revocation of a conditional
18prescription license or prescription license.
 
19    (225 ILCS 15/7)  (from Ch. 111, par. 5357)
20    (Section scheduled to be repealed on January 1, 2017)
21    Sec. 7. Board. The Secretary shall appoint a Board that
22shall serve in an advisory capacity to the Secretary.
23    The Board shall consist of 10 7 persons, 4 of whom are
24licensed clinical psychologists, and actively engaged in the

 

 

09800SB2187ham002- 21 -LRB098 10555 ZMM 58174 a

1practice of clinical psychology, 3 of whom are licensed
2prescribing psychologists, 2 of whom are licensed clinical
3psychologists and are full time faculty members of accredited
4colleges or universities who are engaged in training clinical
5psychologists, and one of whom is a public member who is not a
6licensed health care provider. In appointing members of the
7Board, the Secretary shall give due consideration to the
8adequate representation of the various fields of health care
9psychology such as clinical psychology, school psychology and
10counseling psychology. In appointing members of the Board, the
11Secretary shall give due consideration to recommendations by
12members of the profession of clinical psychology and by the
13State-wide organizations representing the interests of
14clinical psychologists and organizations representing the
15interests of academic programs as well as recommendations by
16approved doctoral level psychology programs in the State of
17Illinois. The members shall be appointed for a term of 4 years.
18No member shall be eligible to serve for more than 2 full
19terms. Any appointment to fill a vacancy shall be for the
20unexpired portion of the term. A member appointed to fill a
21vacancy for an unexpired term for a duration of 2 years or more
22may be reappointed for a maximum of one term and a member
23appointed to fill a vacancy for an unexpired term for a
24duration of less than 2 years may be reappointed for a maximum
25of 2 terms. The Secretary may remove any member for cause at
26any time prior to the expiration of his or her term.

 

 

09800SB2187ham002- 22 -LRB098 10555 ZMM 58174 a

1    The 3 initial appointees to the Board who are licensed
2prescribing psychologists may hold a medical or prescription
3license issued by another state so long as the license is
4deemed by the Secretary to be substantially equivalent to a
5prescription license under this Act. Such initial appointees
6shall serve on the Board until the Board adopts rules pursuant
7to Section 4.8 of this Act providing for the procedures to be
8followed in obtaining prescription licenses in this State.
9    The Board shall annually elect one of its members as
10chairperson and vice chairperson.
11    The members of the Board shall be reimbursed for all
12authorized legitimate and necessary expenses incurred in
13attending the meetings of the Board.
14    The Secretary shall give due consideration to all
15recommendations of the Board. In the event the Secretary
16disagrees with or takes action contrary to the recommendation
17of the Board, he or she shall provide the Board with a written
18and specific explanation of his or her actions.
19    The Board may make recommendations on all matters relating
20to continuing education including the number of hours necessary
21for license renewal, waivers for those unable to meet such
22requirements and acceptable course content. Such
23recommendations shall not impose an undue burden on the
24Department or an unreasonable restriction on those seeking
25license renewal.
26    Seven Four members shall constitute a quorum. A quorum is

 

 

09800SB2187ham002- 23 -LRB098 10555 ZMM 58174 a

1required for all Board decisions.
2    Members of the Board shall have no liability in any action
3based upon any disciplinary proceeding or other activity
4performed in good faith as a member of the Board.
5    The Secretary may terminate the appointment of any member
6for cause which in the opinion of the Secretary reasonably
7justifies such termination.
8(Source: P.A. 96-1050, eff. 1-1-11.)
 
9    Section 10. The Medical Practice Act of 1987 is amended by
10changing Section 54.5 as follows:
 
11    (225 ILCS 60/54.5)
12    (Section scheduled to be repealed on December 31, 2014)
13    Sec. 54.5. Physician delegation of authority to physician
14assistants and advanced practice nurses.
15    (a) Physicians licensed to practice medicine in all its
16branches may delegate care and treatment responsibilities to a
17physician assistant under guidelines in accordance with the
18requirements of the Physician Assistant Practice Act of 1987. A
19physician licensed to practice medicine in all its branches may
20enter into supervising physician agreements with no more than 5
21physician assistants as set forth in subsection (a) of Section
227 of the Physician Assistant Practice Act of 1987.
23    (b) A physician licensed to practice medicine in all its
24branches in active clinical practice may collaborate with an

 

 

09800SB2187ham002- 24 -LRB098 10555 ZMM 58174 a

1advanced practice nurse in accordance with the requirements of
2the Nurse Practice Act. Collaboration is for the purpose of
3providing medical consultation, and no employment relationship
4is required. A written collaborative agreement shall conform to
5the requirements of Section 65-35 of the Nurse Practice Act.
6The written collaborative agreement shall be for services the
7collaborating physician generally provides or may provide in
8his or her clinical medical practice. A written collaborative
9agreement shall be adequate with respect to collaboration with
10advanced practice nurses if all of the following apply:
11        (1) The agreement is written to promote the exercise of
12    professional judgment by the advanced practice nurse
13    commensurate with his or her education and experience. The
14    agreement need not describe the exact steps that an
15    advanced practice nurse must take with respect to each
16    specific condition, disease, or symptom, but must specify
17    those procedures that require a physician's presence as the
18    procedures are being performed.
19        (2) Practice guidelines and orders are developed and
20    approved jointly by the advanced practice nurse and
21    collaborating physician, as needed, based on the practice
22    of the practitioners. Such guidelines and orders and the
23    patient services provided thereunder are periodically
24    reviewed by the collaborating physician.
25        (3) The advance practice nurse provides services the
26    collaborating physician generally provides or may provide

 

 

09800SB2187ham002- 25 -LRB098 10555 ZMM 58174 a

1    in his or her clinical medical practice, except as set
2    forth in subsection (b-5) of this Section. With respect to
3    labor and delivery, the collaborating physician must
4    provide delivery services in order to participate with a
5    certified nurse midwife.
6        (4) The collaborating physician and advanced practice
7    nurse consult at least once a month to provide
8    collaboration and consultation.
9        (5) Methods of communication are available with the
10    collaborating physician in person or through
11    telecommunications for consultation, collaboration, and
12    referral as needed to address patient care needs.
13        (6) The agreement contains provisions detailing notice
14    for termination or change of status involving a written
15    collaborative agreement, except when such notice is given
16    for just cause.
17    (b-5) An anesthesiologist or physician licensed to
18practice medicine in all its branches may collaborate with a
19certified registered nurse anesthetist in accordance with
20Section 65-35 of the Nurse Practice Act for the provision of
21anesthesia services. With respect to the provision of
22anesthesia services, the collaborating anesthesiologist or
23physician shall have training and experience in the delivery of
24anesthesia services consistent with Department rules.
25Collaboration shall be adequate if:
26        (1) an anesthesiologist or a physician participates in

 

 

09800SB2187ham002- 26 -LRB098 10555 ZMM 58174 a

1    the joint formulation and joint approval of orders or
2    guidelines and periodically reviews such orders and the
3    services provided patients under such orders; and
4        (2) for anesthesia services, the anesthesiologist or
5    physician participates through discussion of and agreement
6    with the anesthesia plan and is physically present and
7    available on the premises during the delivery of anesthesia
8    services for diagnosis, consultation, and treatment of
9    emergency medical conditions. Anesthesia services in a
10    hospital shall be conducted in accordance with Section 10.7
11    of the Hospital Licensing Act and in an ambulatory surgical
12    treatment center in accordance with Section 6.5 of the
13    Ambulatory Surgical Treatment Center Act.
14    (b-10) The anesthesiologist or operating physician must
15agree with the anesthesia plan prior to the delivery of
16services.
17    (c) The supervising physician shall have access to the
18medical records of all patients attended by a physician
19assistant. The collaborating physician shall have access to the
20medical records of all patients attended to by an advanced
21practice nurse.
22    (d) (Blank).
23    (e) A physician shall not be liable for the acts or
24omissions of a prescribing psychologist, physician assistant,
25or advanced practice nurse solely on the basis of having signed
26a supervision agreement or guidelines or a collaborative

 

 

09800SB2187ham002- 27 -LRB098 10555 ZMM 58174 a

1agreement, an order, a standing medical order, a standing
2delegation order, or other order or guideline authorizing a
3prescribing psychologist, physician assistant, or advanced
4practice nurse to perform acts, unless the physician has reason
5to believe the prescribing psychologist, physician assistant,
6or advanced practice nurse lacked the competency to perform the
7act or acts or commits willful and wanton misconduct.
8    (f) A collaborating physician may, but is not required to,
9delegate prescriptive authority to an advanced practice nurse
10as part of a written collaborative agreement, and the
11delegation of prescriptive authority shall conform to the
12requirements of Section 65-40 of the Nurse Practice Act.
13    (g) A supervising physician may, but is not required to,
14delegate prescriptive authority to a physician assistant as
15part of a written supervision agreement, and the delegation of
16prescriptive authority shall conform to the requirements of
17Section 7.5 of the Physician Assistant Practice Act of 1987.
18    (h) For the purposes of this Section, "generally provides
19or may provide in his or her clinical medical practice" means
20categories of care or treatment, not specific tasks or duties,
21that the physician provides individually or through delegation
22to other persons so that the physician has the experience and
23ability to provide collaboration and consultation. This
24definition shall not be construed to prohibit an advanced
25practice nurse from providing primary health treatment or care
26within the scope of his or her training and experience,

 

 

09800SB2187ham002- 28 -LRB098 10555 ZMM 58174 a

1including, but not limited to, health screenings, patient
2histories, physical examinations, women's health examinations,
3or school physicals that may be provided as part of the routine
4practice of an advanced practice nurse or on a volunteer basis.
5    (i) A supervising physician shall delegate prescriptive
6authority to a conditionally licensed prescribing psychologist
7as part of a written supervision agreement, and the delegation
8of prescriptive authority shall conform to the requirements of
9Section 4.2 of the Clinical Psychologist Licensing Act.
10    (j) A collaborating physician shall delegate prescriptive
11authority to a fully licensed prescribing psychologist as part
12of a written collaborative agreement, and the delegation of
13prescriptive authority shall conform to the requirements of
14Section 4.4 of the Clinical Psychologist Licensing Act.
15(Source: P.A. 97-358, eff. 8-12-11; 97-1071, eff. 8-24-12;
1698-192, eff. 1-1-14.)
 
17    Section 15. The Illinois Controlled Substances Act is
18amended by changing Section 102 as follows:
 
19    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
20    Sec. 102. Definitions. As used in this Act, unless the
21context otherwise requires:
22    (a) "Addict" means any person who habitually uses any drug,
23chemical, substance or dangerous drug other than alcohol so as
24to endanger the public morals, health, safety or welfare or who

 

 

09800SB2187ham002- 29 -LRB098 10555 ZMM 58174 a

1is so far addicted to the use of a dangerous drug or controlled
2substance other than alcohol as to have lost the power of self
3control with reference to his or her addiction.
4    (b) "Administer" means the direct application of a
5controlled substance, whether by injection, inhalation,
6ingestion, or any other means, to the body of a patient,
7research subject, or animal (as defined by the Humane
8Euthanasia in Animal Shelters Act) by:
9        (1) a practitioner (or, in his or her presence, by his
10    or her authorized agent),
11        (2) the patient or research subject pursuant to an
12    order, or
13        (3) a euthanasia technician as defined by the Humane
14    Euthanasia in Animal Shelters Act.
15    (c) "Agent" means an authorized person who acts on behalf
16of or at the direction of a manufacturer, distributor,
17dispenser, prescriber, or practitioner. It does not include a
18common or contract carrier, public warehouseman or employee of
19the carrier or warehouseman.
20    (c-1) "Anabolic Steroids" means any drug or hormonal
21substance, chemically and pharmacologically related to
22testosterone (other than estrogens, progestins,
23corticosteroids, and dehydroepiandrosterone), and includes:
24    (i) 3[beta],17-dihydroxy-5a-androstane, 
25    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
26    (iii) 5[alpha]-androstan-3,17-dione, 

 

 

09800SB2187ham002- 30 -LRB098 10555 ZMM 58174 a

1    (iv) 1-androstenediol (3[beta], 
2        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
3    (v) 1-androstenediol (3[alpha], 
4        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
5    (vi) 4-androstenediol  
6        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
7    (vii) 5-androstenediol  
8        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
9    (viii) 1-androstenedione  
10        ([5alpha]-androst-1-en-3,17-dione), 
11    (ix) 4-androstenedione  
12        (androst-4-en-3,17-dione), 
13    (x) 5-androstenedione  
14        (androst-5-en-3,17-dione), 
15    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
16        hydroxyandrost-4-en-3-one), 
17    (xii) boldenone (17[beta]-hydroxyandrost- 
18        1,4,-diene-3-one), 
19    (xiii) boldione (androsta-1,4- 
20        diene-3,17-dione), 
21    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
22        [beta]-hydroxyandrost-4-en-3-one), 
23    (xv) clostebol (4-chloro-17[beta]- 
24        hydroxyandrost-4-en-3-one), 
25    (xvi) dehydrochloromethyltestosterone (4-chloro- 
26        17[beta]-hydroxy-17[alpha]-methyl- 

 

 

09800SB2187ham002- 31 -LRB098 10555 ZMM 58174 a

1        androst-1,4-dien-3-one), 
2    (xvii) desoxymethyltestosterone 
3    (17[alpha]-methyl-5[alpha] 
4        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
5    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
6        '1-testosterone') (17[beta]-hydroxy- 
7        5[alpha]-androst-1-en-3-one), 
8    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
9        androstan-3-one), 
10    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
11        5[alpha]-androstan-3-one), 
12    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
13        hydroxyestr-4-ene), 
14    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
15        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
16    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
17        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
18    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
19        hydroxyandrostano[2,3-c]-furazan), 
20    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
21    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
22        androst-4-en-3-one), 
23    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
24        dihydroxy-estr-4-en-3-one), 
25    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
26        hydroxy-5-androstan-3-one), 

 

 

09800SB2187ham002- 32 -LRB098 10555 ZMM 58174 a

1    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
2        [5a]-androstan-3-one), 
3    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
4        hydroxyandrost-1,4-dien-3-one), 
5    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
6        dihydroxyandrost-5-ene), 
7    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
8        5[alpha]-androst-1-en-3-one), 
9    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
10        dihydroxy-5a-androstane), 
11    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
12        -5a-androstane), 
13    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
14        dihydroxyandrost-4-ene), 
15    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
16        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
17    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
18        hydroxyestra-4,9(10)-dien-3-one), 
19    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
20        hydroxyestra-4,9-11-trien-3-one), 
21    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
22        hydroxyandrost-4-en-3-one), 
23    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
24        hydroxyestr-4-en-3-one), 
25    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
26        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 

 

 

09800SB2187ham002- 33 -LRB098 10555 ZMM 58174 a

1        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
2        1-testosterone'), 
3    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
4    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
5        dihydroxyestr-4-ene), 
6    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
7        dihydroxyestr-4-ene), 
8    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
9        dihydroxyestr-5-ene), 
10    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
11        dihydroxyestr-5-ene), 
12    (xlvii) 19-nor-4,9(10)-androstadienedione  
13        (estra-4,9(10)-diene-3,17-dione), 
14    (xlviii) 19-nor-4-androstenedione (estr-4- 
15        en-3,17-dione), 
16    (xlix) 19-nor-5-androstenedione (estr-5- 
17        en-3,17-dione), 
18    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
19        hydroxygon-4-en-3-one), 
20    (li) norclostebol (4-chloro-17[beta]- 
21        hydroxyestr-4-en-3-one), 
22    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
23        hydroxyestr-4-en-3-one), 
24    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
25        hydroxyestr-4-en-3-one), 
26    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 

 

 

09800SB2187ham002- 34 -LRB098 10555 ZMM 58174 a

1        2-oxa-5[alpha]-androstan-3-one), 
2    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
3        dihydroxyandrost-4-en-3-one), 
4    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
5        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
6    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
7        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
8    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
9        (5[alpha]-androst-1-en-3-one), 
10    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
11        secoandrosta-1,4-dien-17-oic 
12        acid lactone), 
13    (lx) testosterone (17[beta]-hydroxyandrost- 
14        4-en-3-one), 
15    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
16        diethyl-17[beta]-hydroxygon- 
17        4,9,11-trien-3-one), 
18    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
19        11-trien-3-one). 
20    Any person who is otherwise lawfully in possession of an
21anabolic steroid, or who otherwise lawfully manufactures,
22distributes, dispenses, delivers, or possesses with intent to
23deliver an anabolic steroid, which anabolic steroid is
24expressly intended for and lawfully allowed to be administered
25through implants to livestock or other nonhuman species, and
26which is approved by the Secretary of Health and Human Services

 

 

09800SB2187ham002- 35 -LRB098 10555 ZMM 58174 a

1for such administration, and which the person intends to
2administer or have administered through such implants, shall
3not be considered to be in unauthorized possession or to
4unlawfully manufacture, distribute, dispense, deliver, or
5possess with intent to deliver such anabolic steroid for
6purposes of this Act.
7    (d) "Administration" means the Drug Enforcement
8Administration, United States Department of Justice, or its
9successor agency.
10    (d-5) "Clinical Director, Prescription Monitoring Program"
11means a Department of Human Services administrative employee
12licensed to either prescribe or dispense controlled substances
13who shall run the clinical aspects of the Department of Human
14Services Prescription Monitoring Program and its Prescription
15Information Library.
16    (d-10) "Compounding" means the preparation and mixing of
17components, excluding flavorings, (1) as the result of a
18prescriber's prescription drug order or initiative based on the
19prescriber-patient-pharmacist relationship in the course of
20professional practice or (2) for the purpose of, or incident
21to, research, teaching, or chemical analysis and not for sale
22or dispensing. "Compounding" includes the preparation of drugs
23or devices in anticipation of receiving prescription drug
24orders based on routine, regularly observed dispensing
25patterns. Commercially available products may be compounded
26for dispensing to individual patients only if both of the

 

 

09800SB2187ham002- 36 -LRB098 10555 ZMM 58174 a

1following conditions are met: (i) the commercial product is not
2reasonably available from normal distribution channels in a
3timely manner to meet the patient's needs and (ii) the
4prescribing practitioner has requested that the drug be
5compounded.
6    (e) "Control" means to add a drug or other substance, or
7immediate precursor, to a Schedule whether by transfer from
8another Schedule or otherwise.
9    (f) "Controlled Substance" means (i) a drug, substance, or
10immediate precursor in the Schedules of Article II of this Act
11or (ii) a drug or other substance, or immediate precursor,
12designated as a controlled substance by the Department through
13administrative rule. The term does not include distilled
14spirits, wine, malt beverages, or tobacco, as those terms are
15defined or used in the Liquor Control Act of 1934 and the
16Tobacco Products Tax Act of 1995.
17    (f-5) "Controlled substance analog" means a substance:
18        (1) the chemical structure of which is substantially
19    similar to the chemical structure of a controlled substance
20    in Schedule I or II;
21        (2) which has a stimulant, depressant, or
22    hallucinogenic effect on the central nervous system that is
23    substantially similar to or greater than the stimulant,
24    depressant, or hallucinogenic effect on the central
25    nervous system of a controlled substance in Schedule I or
26    II; or

 

 

09800SB2187ham002- 37 -LRB098 10555 ZMM 58174 a

1        (3) with respect to a particular person, which such
2    person represents or intends to have a stimulant,
3    depressant, or hallucinogenic effect on the central
4    nervous system that is substantially similar to or greater
5    than the stimulant, depressant, or hallucinogenic effect
6    on the central nervous system of a controlled substance in
7    Schedule I or II.
8    (g) "Counterfeit substance" means a controlled substance,
9which, or the container or labeling of which, without
10authorization bears the trademark, trade name, or other
11identifying mark, imprint, number or device, or any likeness
12thereof, of a manufacturer, distributor, or dispenser other
13than the person who in fact manufactured, distributed, or
14dispensed the substance.
15    (h) "Deliver" or "delivery" means the actual, constructive
16or attempted transfer of possession of a controlled substance,
17with or without consideration, whether or not there is an
18agency relationship.
19    (i) "Department" means the Illinois Department of Human
20Services (as successor to the Department of Alcoholism and
21Substance Abuse) or its successor agency.
22    (j) (Blank).
23    (k) "Department of Corrections" means the Department of
24Corrections of the State of Illinois or its successor agency.
25    (l) "Department of Financial and Professional Regulation"
26means the Department of Financial and Professional Regulation

 

 

09800SB2187ham002- 38 -LRB098 10555 ZMM 58174 a

1of the State of Illinois or its successor agency.
2    (m) "Depressant" means any drug that (i) causes an overall
3depression of central nervous system functions, (ii) causes
4impaired consciousness and awareness, and (iii) can be
5habit-forming or lead to a substance abuse problem, including
6but not limited to alcohol, cannabis and its active principles
7and their analogs, benzodiazepines and their analogs,
8barbiturates and their analogs, opioids (natural and
9synthetic) and their analogs, and chloral hydrate and similar
10sedative hypnotics.
11    (n) (Blank).
12    (o) "Director" means the Director of the Illinois State
13Police or his or her designated agents.
14    (p) "Dispense" means to deliver a controlled substance to
15an ultimate user or research subject by or pursuant to the
16lawful order of a prescriber, including the prescribing,
17administering, packaging, labeling, or compounding necessary
18to prepare the substance for that delivery.
19    (q) "Dispenser" means a practitioner who dispenses.
20    (r) "Distribute" means to deliver, other than by
21administering or dispensing, a controlled substance.
22    (s) "Distributor" means a person who distributes.
23    (t) "Drug" means (1) substances recognized as drugs in the
24official United States Pharmacopoeia, Official Homeopathic
25Pharmacopoeia of the United States, or official National
26Formulary, or any supplement to any of them; (2) substances

 

 

09800SB2187ham002- 39 -LRB098 10555 ZMM 58174 a

1intended for use in diagnosis, cure, mitigation, treatment, or
2prevention of disease in man or animals; (3) substances (other
3than food) intended to affect the structure of any function of
4the body of man or animals and (4) substances intended for use
5as a component of any article specified in clause (1), (2), or
6(3) of this subsection. It does not include devices or their
7components, parts, or accessories.
8    (t-5) "Euthanasia agency" means an entity certified by the
9Department of Financial and Professional Regulation for the
10purpose of animal euthanasia that holds an animal control
11facility license or animal shelter license under the Animal
12Welfare Act. A euthanasia agency is authorized to purchase,
13store, possess, and utilize Schedule II nonnarcotic and
14Schedule III nonnarcotic drugs for the sole purpose of animal
15euthanasia.
16    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
17substances (nonnarcotic controlled substances) that are used
18by a euthanasia agency for the purpose of animal euthanasia.
19    (u) "Good faith" means the prescribing or dispensing of a
20controlled substance by a practitioner in the regular course of
21professional treatment to or for any person who is under his or
22her treatment for a pathology or condition other than that
23individual's physical or psychological dependence upon or
24addiction to a controlled substance, except as provided herein:
25and application of the term to a pharmacist shall mean the
26dispensing of a controlled substance pursuant to the

 

 

09800SB2187ham002- 40 -LRB098 10555 ZMM 58174 a

1prescriber's order which in the professional judgment of the
2pharmacist is lawful. The pharmacist shall be guided by
3accepted professional standards including, but not limited to
4the following, in making the judgment:
5        (1) lack of consistency of prescriber-patient
6    relationship,
7        (2) frequency of prescriptions for same drug by one
8    prescriber for large numbers of patients,
9        (3) quantities beyond those normally prescribed,
10        (4) unusual dosages (recognizing that there may be
11    clinical circumstances where more or less than the usual
12    dose may be used legitimately),
13        (5) unusual geographic distances between patient,
14    pharmacist and prescriber,
15        (6) consistent prescribing of habit-forming drugs.
16    (u-0.5) "Hallucinogen" means a drug that causes markedly
17altered sensory perception leading to hallucinations of any
18type.
19    (u-1) "Home infusion services" means services provided by a
20pharmacy in compounding solutions for direct administration to
21a patient in a private residence, long-term care facility, or
22hospice setting by means of parenteral, intravenous,
23intramuscular, subcutaneous, or intraspinal infusion.
24    (u-5) "Illinois State Police" means the State Police of the
25State of Illinois, or its successor agency.
26    (v) "Immediate precursor" means a substance:

 

 

09800SB2187ham002- 41 -LRB098 10555 ZMM 58174 a

1        (1) which the Department has found to be and by rule
2    designated as being a principal compound used, or produced
3    primarily for use, in the manufacture of a controlled
4    substance;
5        (2) which is an immediate chemical intermediary used or
6    likely to be used in the manufacture of such controlled
7    substance; and
8        (3) the control of which is necessary to prevent,
9    curtail or limit the manufacture of such controlled
10    substance.
11    (w) "Instructional activities" means the acts of teaching,
12educating or instructing by practitioners using controlled
13substances within educational facilities approved by the State
14Board of Education or its successor agency.
15    (x) "Local authorities" means a duly organized State,
16County or Municipal peace unit or police force.
17    (y) "Look-alike substance" means a substance, other than a
18controlled substance which (1) by overall dosage unit
19appearance, including shape, color, size, markings or lack
20thereof, taste, consistency, or any other identifying physical
21characteristic of the substance, would lead a reasonable person
22to believe that the substance is a controlled substance, or (2)
23is expressly or impliedly represented to be a controlled
24substance or is distributed under circumstances which would
25lead a reasonable person to believe that the substance is a
26controlled substance. For the purpose of determining whether

 

 

09800SB2187ham002- 42 -LRB098 10555 ZMM 58174 a

1the representations made or the circumstances of the
2distribution would lead a reasonable person to believe the
3substance to be a controlled substance under this clause (2) of
4subsection (y), the court or other authority may consider the
5following factors in addition to any other factor that may be
6relevant:
7        (a) statements made by the owner or person in control
8    of the substance concerning its nature, use or effect;
9        (b) statements made to the buyer or recipient that the
10    substance may be resold for profit;
11        (c) whether the substance is packaged in a manner
12    normally used for the illegal distribution of controlled
13    substances;
14        (d) whether the distribution or attempted distribution
15    included an exchange of or demand for money or other
16    property as consideration, and whether the amount of the
17    consideration was substantially greater than the
18    reasonable retail market value of the substance.
19    Clause (1) of this subsection (y) shall not apply to a
20noncontrolled substance in its finished dosage form that was
21initially introduced into commerce prior to the initial
22introduction into commerce of a controlled substance in its
23finished dosage form which it may substantially resemble.
24    Nothing in this subsection (y) prohibits the dispensing or
25distributing of noncontrolled substances by persons authorized
26to dispense and distribute controlled substances under this

 

 

09800SB2187ham002- 43 -LRB098 10555 ZMM 58174 a

1Act, provided that such action would be deemed to be carried
2out in good faith under subsection (u) if the substances
3involved were controlled substances.
4    Nothing in this subsection (y) or in this Act prohibits the
5manufacture, preparation, propagation, compounding,
6processing, packaging, advertising or distribution of a drug or
7drugs by any person registered pursuant to Section 510 of the
8Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
9    (y-1) "Mail-order pharmacy" means a pharmacy that is
10located in a state of the United States that delivers,
11dispenses or distributes, through the United States Postal
12Service or other common carrier, to Illinois residents, any
13substance which requires a prescription.
14    (z) "Manufacture" means the production, preparation,
15propagation, compounding, conversion or processing of a
16controlled substance other than methamphetamine, either
17directly or indirectly, by extraction from substances of
18natural origin, or independently by means of chemical
19synthesis, or by a combination of extraction and chemical
20synthesis, and includes any packaging or repackaging of the
21substance or labeling of its container, except that this term
22does not include:
23        (1) by an ultimate user, the preparation or compounding
24    of a controlled substance for his or her own use; or
25        (2) by a practitioner, or his or her authorized agent
26    under his or her supervision, the preparation,

 

 

09800SB2187ham002- 44 -LRB098 10555 ZMM 58174 a

1    compounding, packaging, or labeling of a controlled
2    substance:
3            (a) as an incident to his or her administering or
4        dispensing of a controlled substance in the course of
5        his or her professional practice; or
6            (b) as an incident to lawful research, teaching or
7        chemical analysis and not for sale.
8    (z-1) (Blank).
9    (z-5) "Medication shopping" means the conduct prohibited
10under subsection (a) of Section 314.5 of this Act.
11    (z-10) "Mid-level practitioner" means (i) a physician
12assistant who has been delegated authority to prescribe through
13a written delegation of authority by a physician licensed to
14practice medicine in all of its branches, in accordance with
15Section 7.5 of the Physician Assistant Practice Act of 1987,
16(ii) an advanced practice nurse who has been delegated
17authority to prescribe through a written delegation of
18authority by a physician licensed to practice medicine in all
19of its branches or by a podiatric physician, in accordance with
20Section 65-40 of the Nurse Practice Act, or (iii) an animal
21euthanasia agency.
22    (aa) "Narcotic drug" means any of the following, whether
23produced directly or indirectly by extraction from substances
24of vegetable origin, or independently by means of chemical
25synthesis, or by a combination of extraction and chemical
26synthesis:

 

 

09800SB2187ham002- 45 -LRB098 10555 ZMM 58174 a

1        (1) opium, opiates, derivatives of opium and opiates,
2    including their isomers, esters, ethers, salts, and salts
3    of isomers, esters, and ethers, whenever the existence of
4    such isomers, esters, ethers, and salts is possible within
5    the specific chemical designation; however the term
6    "narcotic drug" does not include the isoquinoline
7    alkaloids of opium;
8        (2) (blank);
9        (3) opium poppy and poppy straw;
10        (4) coca leaves, except coca leaves and extracts of
11    coca leaves from which substantially all of the cocaine and
12    ecgonine, and their isomers, derivatives and salts, have
13    been removed;
14        (5) cocaine, its salts, optical and geometric isomers,
15    and salts of isomers;
16        (6) ecgonine, its derivatives, their salts, isomers,
17    and salts of isomers;
18        (7) any compound, mixture, or preparation which
19    contains any quantity of any of the substances referred to
20    in subparagraphs (1) through (6).
21    (bb) "Nurse" means a registered nurse licensed under the
22Nurse Practice Act.
23    (cc) (Blank).
24    (dd) "Opiate" means any substance having an addiction
25forming or addiction sustaining liability similar to morphine
26or being capable of conversion into a drug having addiction

 

 

09800SB2187ham002- 46 -LRB098 10555 ZMM 58174 a

1forming or addiction sustaining liability.
2    (ee) "Opium poppy" means the plant of the species Papaver
3somniferum L., except its seeds.
4    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
5solution or other liquid form of medication intended for
6administration by mouth, but the term does not include a form
7of medication intended for buccal, sublingual, or transmucosal
8administration.
9    (ff) "Parole and Pardon Board" means the Parole and Pardon
10Board of the State of Illinois or its successor agency.
11    (gg) "Person" means any individual, corporation,
12mail-order pharmacy, government or governmental subdivision or
13agency, business trust, estate, trust, partnership or
14association, or any other entity.
15    (hh) "Pharmacist" means any person who holds a license or
16certificate of registration as a registered pharmacist, a local
17registered pharmacist or a registered assistant pharmacist
18under the Pharmacy Practice Act.
19    (ii) "Pharmacy" means any store, ship or other place in
20which pharmacy is authorized to be practiced under the Pharmacy
21Practice Act.
22    (ii-5) "Pharmacy shopping" means the conduct prohibited
23under subsection (b) of Section 314.5 of this Act.
24    (ii-10) "Physician" (except when the context otherwise
25requires) means a person licensed to practice medicine in all
26of its branches.

 

 

09800SB2187ham002- 47 -LRB098 10555 ZMM 58174 a

1    (jj) "Poppy straw" means all parts, except the seeds, of
2the opium poppy, after mowing.
3    (kk) "Practitioner" means a physician licensed to practice
4medicine in all its branches, dentist, optometrist, podiatric
5physician, veterinarian, scientific investigator, pharmacist,
6physician assistant, advanced practice nurse, licensed
7practical nurse, registered nurse, hospital, laboratory, or
8pharmacy, or other person licensed, registered, or otherwise
9lawfully permitted by the United States or this State to
10distribute, dispense, conduct research with respect to,
11administer or use in teaching or chemical analysis, a
12controlled substance in the course of professional practice or
13research.
14    (ll) "Pre-printed prescription" means a written
15prescription upon which the designated drug has been indicated
16prior to the time of issuance; the term does not mean a written
17prescription that is individually generated by machine or
18computer in the prescriber's office.
19    (mm) "Prescriber" means a physician licensed to practice
20medicine in all its branches, dentist, optometrist,
21prescribing psychologist licensed under the Clinical
22Psychologist Licensing Act, podiatric physician, or
23veterinarian who issues a prescription, a physician assistant
24who issues a prescription for a controlled substance in
25accordance with Section 303.05, a written delegation, and a
26written supervision agreement required under Section 7.5 of the

 

 

09800SB2187ham002- 48 -LRB098 10555 ZMM 58174 a

1Physician Assistant Practice Act of 1987, or an advanced
2practice nurse with prescriptive authority delegated under
3Section 65-40 of the Nurse Practice Act and in accordance with
4Section 303.05, a written delegation, and a written
5collaborative agreement under Section 65-35 of the Nurse
6Practice Act.
7    (nn) "Prescription" means a written, facsimile, or oral
8order, or an electronic order that complies with applicable
9federal requirements, of a physician licensed to practice
10medicine in all its branches, dentist, podiatric physician or
11veterinarian for any controlled substance, of an optometrist
12for a Schedule III, IV, or V controlled substance in accordance
13with Section 15.1 of the Illinois Optometric Practice Act of
141987, of a physician assistant for a controlled substance in
15accordance with Section 303.05, a written delegation, and a
16written supervision agreement required under Section 7.5 of the
17Physician Assistant Practice Act of 1987, or of an advanced
18practice nurse with prescriptive authority delegated under
19Section 65-40 of the Nurse Practice Act who issues a
20prescription for a controlled substance in accordance with
21Section 303.05, a written delegation, and a written
22collaborative agreement under Section 65-35 of the Nurse
23Practice Act when required by law.
24    (nn-5) "Prescription Information Library" (PIL) means an
25electronic library that contains reported controlled substance
26data.

 

 

09800SB2187ham002- 49 -LRB098 10555 ZMM 58174 a

1    (nn-10) "Prescription Monitoring Program" (PMP) means the
2entity that collects, tracks, and stores reported data on
3controlled substances and select drugs pursuant to Section 316.
4    (oo) "Production" or "produce" means manufacture,
5planting, cultivating, growing, or harvesting of a controlled
6substance other than methamphetamine.
7    (pp) "Registrant" means every person who is required to
8register under Section 302 of this Act.
9    (qq) "Registry number" means the number assigned to each
10person authorized to handle controlled substances under the
11laws of the United States and of this State.
12    (qq-5) "Secretary" means, as the context requires, either
13the Secretary of the Department or the Secretary of the
14Department of Financial and Professional Regulation, and the
15Secretary's designated agents.
16    (rr) "State" includes the State of Illinois and any state,
17district, commonwealth, territory, insular possession thereof,
18and any area subject to the legal authority of the United
19States of America.
20    (rr-5) "Stimulant" means any drug that (i) causes an
21overall excitation of central nervous system functions, (ii)
22causes impaired consciousness and awareness, and (iii) can be
23habit-forming or lead to a substance abuse problem, including
24but not limited to amphetamines and their analogs,
25methylphenidate and its analogs, cocaine, and phencyclidine
26and its analogs.

 

 

09800SB2187ham002- 50 -LRB098 10555 ZMM 58174 a

1    (ss) "Ultimate user" means a person who lawfully possesses
2a controlled substance for his or her own use or for the use of
3a member of his or her household or for administering to an
4animal owned by him or her or by a member of his or her
5household.
6(Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; revised
711-12-13.)
 
8    Section 99. Effective date. This Act takes effect upon
9becoming law.".